Abstract: Compositions, medicaments, systems, and kits are disclosed that include at least one ex vivo fucosylated cell type, at least one chemokine, and/or at least one matrix scaffold. Methods of producing and using the compositions, medicaments, systems, and kits are also disclosed. In particular (but not by way of limitation), methods of treating at least one auto-immune disease and methods of repairing tissue damage due to injury or progressive disease are also disclosed.

Abstract: Compositions, medicaments, kits, and systems are disclosed that include surface-modified stem cells and hematopoietic enhancers and/or monoclonal antibodies for hematopoietic stem cell transplant therapy. The stem cells are ex vivo fucosylated and may be autologous or allogeneic. The hematopoietic enhancers may be white cell enhancers, red cell enhancers, and/or platelet enhancers. Methods of producing and/or using the compositions, medicaments, kits, and systems are also disclosed. Methods of increasing engraftment of hematopoietic stem cells and myeloid lineage cells upon hematopoietic stem cell therapy are also disclosed.

Abstract: A biomass is provided which consists essentially of cells of dinoflagellates of the class Dinophyceae which have been cultivated to produce high cell mass and high DHA content. Biomass consisting of cells of Crypthecodinium cohnii is preferred. The cells are cultivated in an aerobic fermentor to achieve a cell density of a least 10 grams biomass per liter of nutrient solution by maintaining in the fermentor a dissolved oxygen level of at least about 10% of air saturation, and by inducing a stationary phase with a limiting nitrogen source in the nutrient solution. Under these conditions a single cell oil which contains at least 20% docosahexaenoic acid (DHA) in the triglyceride form at a concentration of at least about 1.5 grams per liter of nutrient solution is produced in the biomass. The biomass is suitable as an aquaculture feed.